//

Allos Therapeutics Inc

Posted Mon, 09/14/2009 - 12:16 by Zefu

Allos Therapeutics Inc

11080 Circlepoint Road, Suite 200
Westminster, CO 80020
USA
Phone: (303) 426-6262
Fax: (303) 412-9160
Email: info@allos.com
Web Site: http://www.allos.com/

A. Company Profile

Allos Therapeutics (NASDAQ:ALTH) is a biopharmaceutical company focused on developing and commercializing small molecule drugs for improving cancer treatments.

B. Products

Product Pipelines
Product Indication Clinical Status
PDX (Pralatrexate) Various cancers Phase I/II
RH1 Various cancers Phase I

1. PDX

PDX (10-propargyl-10-deazaaminopterin, pralatrexate) is an injectable small molecule chemotherapeutic agent that has a superior potency and toxicity profile relative to methotrexate and other related dihydrofolate reductase, or DHFR, inhibitors. Drugs that inhibit DHFR, such as methotrexate, were among the first chemotherapeutic agents discovered. Methotrexate remains one of the most widely applied chemotherapy drugs and is used to treat breast, bladder and head and neck cancers, leukemias and other cancers.

2. RH1

RH1 is a small molecule chemotherapeutic agent that is bioactivated by the enzyme DT-diaphorase, or DTD, which is over-expressed in many tumors relative to normal tissue, including lung, colon, breast and liver tumors. Because RH1 is bioactivated in the presence of DTD, it has the potential to provide targeted drug delivery to these tumor types while limiting the toxicity to normal tissue.